Surrozen (SRZN) Share-based Compensation (2020 - 2026)
Surrozen (SRZN) recorded quarterly Share-based Compensation of $2.1 million in Q1 2026, up 110.08% quarter-over-quarter from $1.0 million in Q4 2025, and up 152.4% on a YoY basis from $834000.0 in Q1 2025.
Surrozen (SRZN) Share-based Compensation (2020 - 2026) Analysis & Trends
Surrozen's Share-based Compensation history runs 7 years deep, the most recent figure standing at $2.1 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 152.4% year-over-year to $2.1 million; the TTM figure through Mar 2026 stood at $5.1 million (up 30.32% YoY), while the FY2025 annual figure was $3.8 million, down 6.78% from the prior year.
- Share-based Compensation was $2.1 million for Q1 2026 at Surrozen, up from $1.0 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $2.1 million in Q1 2026 to a low of $834000.0 in Q1 2025.
- Historically, Share-based Compensation has averaged $1.1 million across 5 years, with a median of $1.0 million in 2024.
- The sharpest annual moves came in 2023 and 2026: Share-based Compensation retreated 24.14% in 2023, then jumped 152.4% in 2026.
- A 5-year view of Share-based Compensation shows it stood at $1.5 million in 2022, then declined by 24.14% to $1.2 million in 2023, then slipped by 23.21% to $900000.0 in 2024, then climbed by 11.33% to $1.0 million in 2025, then soared by 110.08% to $2.1 million in 2026.
- The last three Share-based Compensation figures came in at $2.1 million (Q1 2026), $1.0 million (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 305,000.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 26.47 Mn |
| 10 | Surrozen | 225,877.86 | -106.68 Mn | - | 2.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.11 Mn |
| Mar 31, 2026 | 2.11 Mn |
| Dec 31, 2025 | 1.00 Mn |
| Dec 31, 2025 | 1.00 Mn |
| Sep 30, 2025 | 1.01 Mn |
| Sep 30, 2025 | 1.01 Mn |
| Jun 30, 2025 | 994,000.00 |
| Jun 30, 2025 | 994,000.00 |
| Mar 31, 2025 | 834,000.00 |
| Mar 31, 2025 | 834,000.00 |
| Dec 31, 2024 | 900,000.00 |
| Dec 31, 2024 | 900,000.00 |
| Sep 30, 2024 | 1.04 Mn |
| Sep 30, 2024 | 1.04 Mn |
| Jun 30, 2024 | 1.15 Mn |
| Jun 30, 2024 | 1.15 Mn |
| Mar 31, 2024 | 1.03 Mn |
| Mar 31, 2024 | 1.03 Mn |
| Dec 31, 2023 | 1.17 Mn |
| Dec 31, 2023 | 1.17 Mn |